Menstrual and Hormonal Changes in Breast Cancer Patients Treated By Ad- juvant, Adriamycin and Cyclophosphamide Chemotherapy

Jangi Shawkat Muhialdin  Salai; Nermin Jamal  Abdulqadr; Kawa Faeq   Dizaye

doi:10.56056/amj.2016.11

Authors

Jangi Shawkat Muhialdin Salai Department of Pharmacology and Biophysics, College of Medicine, Hawler Medical University. Department of Oncology at Rizgary Teaching Hospital
Nermin Jamal Abdulqadr Department of pharmacy, Rizgary Teaching Hospital
Kawa Faeq Dizaye Department of Pharmacology and Biophysics, College of Medicine, Hawler Medical University

DOI:

https://doi.org/10.56056/amj.2016.11

Keywords:

Doxorubicin and Cyclophosphamide, Hormonal changes, Amenorrhea

Abstract

Background and Objective: The long term effects of adjuvant chemotherapy are very important in patients with breast cancer. Cytotoxic chemotherapy may induce changes in menstrual cycle to variable extents and even may induce amenorrhea. This study was designed to find out the effect of adjuvant chemotherapy, Doxorubicin and Cyclophosphamide, on ovarian function in patients with early stages breast cancer.

Methods: Thirty premenopausal women with newly diagnosed early breast cancer enrolled in this study. In addition to a proper menstruation history, the following parameters FSH, LH, Estrogen, and Progesterone, were estimated before and after 4 cycles of chemotherapy with another follow-up for menstrual history after 6 months, in each patient.

Results: After 4 cycles of adjuvant Doxorubicin and Cyclophosphamide chemotherapy the mean level of FSH and LH was increased and Estrogen level was decreased, significantly. While, Progesterone level was decreased non-significantly. Menstrual changes detected in most patients after receiving chemotherapy but only %47 of them developed amenorrhea which was persistent after 6 months in %33 of the patients. The induced amenorrhea has found to be related positively with the age of the patient but has no any relation with receptor status, estrogen, progesteron and Her2 (human epidermal growth factor receptor 2), of the tumor and neither with the menstrual phase at which chemotherapy has been given nor with the body mass index.

Conclusions: Adjuvant chemotherapy changes ovarian hormonal levels significantly and induces transient and permanent amenorrhea in patients with early stages breast cancer.

Downloads

Download data is not yet available.

References

Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA cancer j clin. 2014; 64: 9–29.

Reyna C, Lee MC. Breast cancer in young women: special consid- erations in multidisciplinary care. Journal of Multidisciplinary Health- care. 2014; 7: 419–429.

Berry DA, Cronin KA, Plevrotos SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353: 1784-1789.

Early Breast Cancer Trialists’ Collaborative Group. Polychemothera- py for early breast cancer: an overview of the randomized trials. Lancet. 1998; 352: 930–942.

Sukumvanich P, Case LD, Zee KV, et al. Incidence and Time Course of Bleeding After Long-Term Amenorrhea After Breast Cancer Treat- ment, Cancer. 2010; 116: 3102–11.

Bianco AR, Del Mastro L, Gallo C, et al. Prognostic role of amenor- rhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer. 1991; 63: 799–803.

Park IH, Han HS, Lee H, et al. Resumption or persistence of menstru- ation after cytotoxic chemotherapy is a prognostic factor for poor dis- ease-free survival in premenopausal patients with early breast cancer. Annals of Oncology. 2012; 23 (1): 2283–89.

Walshe JM, Denduluri N, Swain SM. Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer. JCO. 2006; 24 (36): 5769-5779.

Padmanabhan N, Howell A, Rubens RD. Mechanism of action of ad- juvant chemotherapy in early breast cancer. Lancet. 1986; 2: 411–414.

Goldhirsch, A, Gelber RD, Castigliore M. The magnitude of endo- crine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol. 1990; 1: 183–188.

Meirow D, Lewis H, Nugent D. et al. Subclinical depletion of pri- mordial follicular reserve in mice treated with cyclophosphamide: clin- ical importance and proposed accurate investigative tool. Hum Reprod. 1999; 14: 1903–07.

Bines J, Oleske DM, Cobleigh MA. Ovarian function in premeno- pausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996; 14: 1718–1729.

Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006; 24:1045-51.

Lutchman SK, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update. 2005; 11: 69–89.

Meng K, Tian W, Zhou M, et al. Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels. World Journal of Surgical Oncology. 2013; 11: 101-105.

Su HI, Sammel MD, Green J, et al. Anti-mullerian hormone and inhibin B are hormone measures of ovarian function in late reproduc- tive-aged breast cancer survivors. Cancer. 2010; 116: 592-599.

Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2012; 9: 466-472.

Rebecca LS, Kimberly DM, Jemal A. Cancer statistics. Ca. A Can- cer Journal for Clinicians. 2014; 64 (2): 9-29.

Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004; 22: 4174-4183.

Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001; 344(26): 1997–2008.

Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncolo- gist. 2006; 11(2): 96–110.

Fornier MN, Modi S, Panageas KS, et al. Incidence of chemother- apy- induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Can- cer. 2005; 104(8): 1575- 79.

Oktay K, Libertella B, Oktem O, et al. The impact of paclitaxel on menstrual function. Breast Cancer Res Treat. 2005; 94: S271.

Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-in- duced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007; 30: 126-132.

Tortora G, Derrickson B. Principles of Anatomy and Physiology (13th ed.). Canada: John Wiley and Sons, 2010.

Steiner AZ. Predicting age at menopause: Hormonal, familial, and menstrual cycle factors to consider. Menopausal Medicine. 2011; 19(2): 1-8.

Gradishar WJ, Schilsky RL. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol. 1989; 16: 425-436.

Bines J, Oleske DM, Cobleigh MA. Ovarian function in premeno- pausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996; 14: 1718-1729.

Minton ES, Munster NP. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002; 9(6): 466-472.

Lower EE, Blau R, Gazder P, et al. The Risk of premature meno- pause induced by chemotherapy for early breast cancer. Journal of Women’s Health & Gender-Based Medicine. 2009; 8(7): 949-954.

Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999; 17:2365–2370

Byrne J, Fears TR, Gail MH, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol. 1992; 166:788–793.

Gorman JR, Usita P, Madlensky L, Pierce JP. Young breast cancer survivors: Their perspectives on treatment decisions and fertility Con- cerns. Cancer Nursing 2011; 34(1): 32–40.

Di Cosimo S., Alimonti A., Ferretti et al. Incidence of chemothera- py-induced amenorrhea depending on the timing of treatment by men- strual cycle phase in women with early breast cancer. Annals of Oncol- ogy. 2004; 15: 1065–1071.

Perez-Fidalgo JA, Rosello S, Garcia-Garre E, et al. Incidence of chemotherapy induced amenorrhea in hormone sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regi- mens. Breast Cancer Res Treat. 2010; 120(1): 245-251.